Qsymia (Phentermine-topiramate) to Reduce Binge Eating/Purging in Patients With Bulimia Nervosa and Binge Eating Disorder
Phase of Trial: Phase I/II
Latest Information Update: 20 Nov 2019
Price : $35 *
At a glance
- Drugs Phentermine/topiramate (Primary)
- Indications Binge-eating disorder; Bulimia nervosa
- Focus Therapeutic Use
- 20 Nov 2019 According to a VIVUS media release, results from the study have been published online in the International Journal of Eating Disorders.
- 20 Nov 2019 Results presented in a VIVUS media release.
- 04 Jul 2018 New trial record